Loading stock data…
Sera Prognostics, Inc. (SERA)
$1.81+0.01 (+0.56%)
After Hours$1.84+0.03 (+1.66%)· Last close Jun 29
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sera Prognostics, Inc. in the Healthcare sector is trading at $1.81 with a market capitalization of $80M. Wall Street consensus targets $5.50 (2 analysts), implying a +203.9% move over the next 12 months. The stock is currently near its 52-week low of $1.56, remaining 31.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +203.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 28) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14,000↑ | $10,000↓ | $16,000↓ | $17,000↓ | $38,000 |
| Gross Profit | -$28,000↑ | -$32,000↓ | -$25,000↓ | -$24,000↓ | -$2,000 |
| Operating Income | -$9.36M↓ | -$8.95M↑ | -$8.98M↑ | -$9.32M↓ | -$9.25M |
| Net Income | -$8.40M↓ | -$7.88M↓ | -$7.81M↑ | -$8.05M↑ | -$8.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.53%
Volume
Today's trading volume
12,060
Recent News
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy
Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SunCar Technology Group And 2 Other Promising Penny Stocks For Savvy Investors
The market has shown positive momentum, climbing 1.3% over the last week and 28% in the past year, with earnings expected to grow by 17% per annum in the coming years. For investors willing to explore beyond well-known companies, penny stocks—often smaller or newer firms—can offer unique opportunities that align with current market growth trends. Despite being an older term, penny stocks remain relevant for those seeking potential value and growth, as they can provide financial strength and...
Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Will Sera Prognostics (NASDAQ:SERA) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Sera Prognostics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Sera Prognostics, Inc.'s Q1 2026 earnings call